This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

28 Feb 2011

Ipsen & Biomérieux Sign Personalized Medicine Pact

Ipsen and BioMérieux announced a collaboration using a theranostics approach to focus on hormone-dependent cancers.

Ipsen and bioMérieux, two French pharma firms, have established a global collaboration around theranostics (personalized diagnostic medicine), with a focus on hormone-dependent cancers. The two companies will combine their expertise and resources to co-develop a personalized approach to medicine based on Ipsen’s portfolio of compounds and bioMérieux’s diagnostic tests.

The companies will jointly identify programs for the co-development of a therapeutic and a companion diagnostic test, particularly in the prevention and treatment of prostate and breast cancers, neuro-endocrine tumors (NETs) and pituitary tumors.

"We are very pleased to build this partnership with Ipsen, which has developed over the years a significant scientific a

Related News